Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03921411 · ClinicalTrials.gov registry record · Phase 2
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03921411 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 20 participants.
The verdict
NCT03921411, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
Interventions
- BIOLOGICAL Nemolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-04-09 |
| Est. Completion | 2020-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03921411
The ClinicalTrials.gov registry entry for NCT03921411 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nemolizumab is the first listed.
NCT03921411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03921411 about?
NCT03921411 is a clinical study titled "A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)". The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
What is the current status of trial NCT03921411?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-04-09. Estimated completion is 2020-08-19.
What interventions are being tested in trial NCT03921411?
The interventions under investigation include: Nemolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03921411?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.